CRO

Q3-2017 CRO Update– The current state of the contract research organization industry continues to be largely shaped by the super mergers of the past. The landscape for mid-sized CRO’s has drastically changed as the revenue gap has widened between mega-CRO’s and the rest of the industry.

Q2-2017 CRO Update– The mergers and acquisitions marketplace was robust in the second quarter of 2017. Several of the industry’s largest players were involved in transactions that are sure to alter the future of the CRO and outsourced research landscape.

Q1-2017 CRO Update– The first quarter of 2017 experienced the same high valuations and favorable market fundamentals in the contract research space that were observed in 2016. Factors driving merger and acquisition activity include a robust pharma pipeline, a growing proportion of drugs under development attributed to smaller pharmaceutical companies, and an increased focus on the development of biologics and biosimilars.

Q4-2016 CRO Update– The last few years have seen a tremendous amount of consolidation in the pharmaceutical space, leading to significant financial changes in the CRO industry. Although the dollars spent on outsourced research continues to rise, CRO’s are competing over a few number of total contracts.

Q3-2016 CRO Update– Outsourced research services continues to experience a shift to a ‘one-stop-shop’ model. As groups recognize the benefits of having a broad array of service offerings under one roof, they have turned to acquisition to fulfil this strategy.

Provident Perspectives– In this Provident Perspective, we will discuss our thoughts on the main trends driving the contract research industry. Through discussions with industry executives, private equity groups, and proprietary research, we have established a list of eight definitive insights into the space and how they are affecting the current M&A marketplace.

Transaction Advisory – Willow Laboratories announced today that it has been acquired by Ampersand Capital Partners. Willow is one of the country’s leading clinical and forensic toxicology laboratories providing urine, hair and saliva testing services to a wide range of healthcare providers including treatment centers, physician practices and other laboratories.

Transaction Advisory – Blue Sky Biotech, Inc. has completed a recapitalization with Boston-based private equity firm Ampersand Ventures. Blue Sky Biotech, based in Massachusetts, is a Contract Research Organization (CRO).

  • “Provident’s depth of experience and practical business savvy was demonstrated in their ability to cut through what sometimes looked like impasse.”

  • “After working with Provident on several transactions, it is evident that their extensive industry knowledge and deal expertise prove to be invaluable to their clients.”

  • ”I have a tremendous amount of appreciation and gratitude to the Provident team for their hard work and diligence throughout this process. Each and every member of the Provident team is excellent at their jobs and it has been a pleasure working with such a professional team. Provident has provided outstanding guidance and counsel, and this deal could never have gotten done without Provident’s leadership.”

  • “Provident listened to our story, confirmed that our business was valuable and made us feel like this was the only transaction important to them.”

  • “While the decision to sell our business was a difficult one, Provident vigilantly represented and protected our best interests throughout the transaction.  Provident was the right choice for Cascade and I would recommend their services to anyone.”

  • “We would not have been successful navigating the process without Provident’s hard work and active participation. They exceeded our expectations and we would highly recommend them to any health care company seeking a knowledgeable and engaged investment banking firm.”

  • “A lot of investment bankers were interviewed, Provident was chosen. Provident delivered. My clients could not be happier.”